Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA9 | Q16790 | 2/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4049018 | 0.85 | CA12 (0.36) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL17369727 | 0.82 | ESR2 (0.37) | HDAC3HDAC1HDAC2HDAC8HDAC6 | |
| SCHEMBL4055086 | 0.80 | MAPT (0.35) | LMNACA12CA1CA2CA4 | |
| SCHEMBL27543617 | 0.80 | LMNA (0.51) | LMNAMAPTMAPK1 | |
| SCHEMBL3308937 | 0.74 | CA12 (0.32) | LMNACA12CA1CA2CA4 | |
| SCHEMBL13397090 | 0.73 | P2RY10 (0.37) | LMNACA12CA1CA2CA4 | |
| SCHEMBL18115167 | 0.72 | EPHX2 (0.38) | HDAC8CA12CA1CA2CA9 | |
| SCHEMBL4047493 | 0.71 | CA12 (0.47) | CA12CA1CA2CA4CA9 | |
| SCHEMBL13397115 | 0.71 | CA1 (0.35) | LMNACA12CA1CA2CA9 | |
| SCHEMBL4055080 | 0.70 | CA12 (0.45) | CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | SPEEDEL EXPERIMENTA AG (CH) | 2009-12-24 | — | — | US | disclosed |
| EP-2061751-A1 | NITRATE ESTERS OF AMINOALCOHOLS | Novartis Ag (CH) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008031811-A1 | NITRATE ESTERS OF AMINOALCOHOLS | SPEEDEL EXPERIMENTA AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318432-A1 | Nitrate esters of aminoalcohols | NOS2, NOS1, NOS3 | HDAC3 2411/4885HDAC1 2001/4885HDAC2 2797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.